Data point towards clinical trials of a light-based keratitis therapy in humans.
Advertisement
Advertisement
Microbial keratitis remains one of the most common reasons a patient loses vision in an eye that need not have been lost. Despite decades of refinement in topical antimicrobial therapy, a substantial proportion of patients still end up with scarring, thinning, neovascularization or, in the worst cases, perforation.
In my own clinical experience, and in the wider literature, two weaknesses explain much of this.
A first-in-class small-molecule Fas inhibitor delivered by intravitreal injection is now under evaluation in more than 324 patients across North America and Europe.